Why Summit Therapeutics Skyrocketed 123% This Week
WEBSep 13, 2024 · Shares of Summit Therapeutics (SMMT 5.31%) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence.
Summit Therapeutics Secures $235 Million in Funding from …
WEBSep 12, 2024 · Summit Therapeutics Inc. (SMMT) is making waves today with a major announcement that has sent its stock price soaring 20.77% to $27.42 as of 12:48 PM EDT. The company has successfully raised a substantial $235 million in a private placement, attracting significant interest from both institutional …
Why Summit Therapeutics Stock Is Soaring Again Today - Yahoo …
WEBSep 12, 2024 · Summit's experimental cancer therapy is the first to beat Keytruda head-to-head in a randomized late-stage clinical trial. Is Summit Therapeutics stock a buy?
Why Summit Therapeutics Rocketed Over 60% Today - Yahoo …
WEBSep 9, 2024 · Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. The biotech firm released the results of a Phase III study on ...
Summit Therapeutics Raises $235 Million - Yahoo Finance
WEBMIAMI, September 12, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company accepted offers from multiple leading biotech institutional ...
Press Releases - Summit Therapeutics
WEBFeb 20, 2024 · Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million. January 20, 2023. Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody. January 5, 2023. Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
Summit Therapeutics’ stock surges as lung-cancer treatment vies …
WEBMay 30, 2024 · Shares of Summit Therapeutics jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck’s blockbuster Keytruda in a late-stage trial.
Keytruda beaten by Summit’s bispecific in NSCLC
WEB3 days ago · On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular endothelial growth factor A and programmed cell death protein 1 (PD-1), head-to-head with Merck's Keytruda, a PD-1 binding checkpoint inhibitor, in non-small cell lung cancer (NSCLC) patients with a PD-L1 ...
Summit Therapeutics' stock surges as lung-cancer treatment vies …
WEBMay 30, 2024 · Shares of Summit Therapeutics Inc. (SMMT) jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stage...
Summit Therapeutics Announces First Patient Treated in Phase III ...
WEBMay 9, 2023 · MENLO PARK, Calif.-- (BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the...